Response to dabrafenib after progression on vemurafenib in a patient with advanced BRAF V600E-mutant bronchial adenocarcinoma

Lung Cancer. 2015 Jan;87(1):85-7. doi: 10.1016/j.lungcan.2014.11.008. Epub 2014 Nov 18.

Abstract

We present the case of a patient with rapidly accelerated fibrosarcoma gene F (BRAF) mutated adenocarcinoma of the lung, responding to BRAF inhibitor dabrafenib after progressing on vemurafenib followed by docetaxel. The present case illustrates the potential benefit of successful rechallenge with a BRAF inhibitor, a well known phenomenon observed in other oncogenic driven molecular subtypes of non-small cell lung cancer (NSCLC) such as epidermal growth factor receptor mutation. Rechallenge with a BRAF inhibitor in BRAF mutated NSCLC should be considered, particularly in the absence of alternative therpateutic options.

Keywords: Adenocarcinoma; BRAF mutation; Lung; NSCLC; Rechallenge; Resistance.

Publication types

  • Case Reports

MeSH terms

  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / drug therapy*
  • Adenocarcinoma / genetics*
  • Antineoplastic Agents / therapeutic use
  • Carcinoma, Bronchogenic / diagnosis
  • Carcinoma, Bronchogenic / drug therapy*
  • Carcinoma, Bronchogenic / genetics*
  • DNA Mutational Analysis
  • Disease Progression
  • Drug Resistance, Neoplasm
  • Humans
  • Imidazoles / therapeutic use*
  • Indoles / therapeutic use
  • Lung Neoplasms / diagnosis
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / genetics*
  • Male
  • Middle Aged
  • Mutation*
  • Neoplasm Staging
  • Oximes / therapeutic use*
  • Positron-Emission Tomography
  • Proto-Oncogene Proteins B-raf / antagonists & inhibitors
  • Proto-Oncogene Proteins B-raf / genetics*
  • Retreatment
  • Sulfonamides / therapeutic use
  • Tomography, X-Ray Computed
  • Treatment Outcome
  • Vemurafenib

Substances

  • Antineoplastic Agents
  • Imidazoles
  • Indoles
  • Oximes
  • Sulfonamides
  • Vemurafenib
  • Proto-Oncogene Proteins B-raf
  • dabrafenib